Published in Cancer Cell on December 08, 2009
Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58
MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A (2011) 4.11
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med (2011) 2.46
MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer (2010) 2.33
Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer (2011) 2.02
Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat (2010) 1.98
MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene (2010) 1.97
MicroRNA in lung cancer. Br J Cancer (2010) 1.97
Environmental chemical exposures and human epigenetics. Int J Epidemiol (2011) 1.97
MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst (2010) 1.94
Roles of small RNAs in tumor formation. Trends Mol Med (2010) 1.89
MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLoS One (2013) 1.82
Retracted miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS One (2013) 1.77
MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett (2012) 1.73
MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One (2013) 1.72
miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ. Oncogene (2011) 1.62
miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene (2011) 1.58
Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta (2014) 1.53
The role of microRNAs in liver cancer progression. Br J Cancer (2010) 1.52
MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci U S A (2012) 1.52
miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res (2011) 1.51
Causes and consequences of microRNA dysregulation. Cancer J (2012) 1.51
miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med (2012) 1.49
Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS One (2011) 1.44
Discriminating metastasised from non-metastasised seminoma based on transcriptional changes in primary tumours using NGS. Br J Cancer (2014) 1.44
NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res (2011) 1.42
Tumor suppressor p53 meets microRNAs. J Mol Cell Biol (2011) 1.39
Cell-free Circulating miRNA Biomarkers in Cancer. J Cancer (2012) 1.37
The role of microRNAs in human liver cancers. Semin Oncol (2011) 1.34
Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-α in breast cancer. Cancer Res (2013) 1.31
Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221. J Biol Chem (2012) 1.28
Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer (2013) 1.27
In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget (2013) 1.26
Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci U S A (2013) 1.24
Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway. Autophagy (2013) 1.22
miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer (2011) 1.19
Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS One (2014) 1.18
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ (2014) 1.17
Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res (2013) 1.16
MiR-221/222 target the DNA methyltransferase MGMT in glioma cells. PLoS One (2013) 1.16
MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. ScientificWorldJournal (2013) 1.16
miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene (2014) 1.15
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med (2013) 1.13
High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med (2012) 1.11
Verticillin A overcomes apoptosis resistance in human colon carcinoma through DNA methylation-dependent upregulation of BNIP3. Cancer Res (2011) 1.11
MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat (2013) 1.11
MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene (2013) 1.09
A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells. Gastroenterology (2014) 1.09
Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury. Sci Transl Med (2012) 1.09
Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One (2010) 1.08
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res (2014) 1.08
microRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3. Exp Ther Med (2011) 1.07
A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. Clin Cancer Res (2013) 1.07
MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int (2014) 1.07
Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. PLoS One (2014) 1.06
The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate (2011) 1.06
MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics (2011) 1.06
Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia (2011) 1.06
MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis (2012) 1.06
A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. J Cancer Res Clin Oncol (2011) 1.05
MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med (2013) 1.05
MetastamiRs: non-coding MicroRNAs driving cancer invasion and metastasis. Int J Mol Sci (2012) 1.04
MicroRNAs, diet, and cancer: new mechanistic insights on the epigenetic actions of phytochemicals. Mol Carcinog (2011) 1.04
Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ (2011) 1.04
Noncoding RNA in oncogenesis: a new era of identifying key players. Int J Mol Sci (2013) 1.03
Mechanistic Roles of Noncoding RNAs in Lung Cancer Biology and Their Clinical Implications. Genet Res Int (2012) 1.03
Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther (2013) 1.02
MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Biosci Rep (2014) 1.02
Regulation of cancer metastasis by cell-free miRNAs. Biochim Biophys Acta (2014) 1.02
Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev (2012) 1.01
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS One (2014) 1.01
miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. Oncol Lett (2012) 1.01
microRNAs and lung cancer: tumors and 22-mers. Cancer Metastasis Rev (2010) 1.01
miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One (2013) 1.00
MicroRNAs and lung cancers: from pathogenesis to clinical implications. Front Med (2012) 1.00
microRNA-222 targeting PTEN promotes neurite outgrowth from adult dorsal root ganglion neurons following sciatic nerve transection. PLoS One (2012) 1.00
MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1. PLoS One (2012) 0.99
Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin. Thyroid Res (2011) 0.99
Applications of MicroRNAs in the Diagnosis and Prognosis of Lung Cancer. Expert Opin Med Diagn (2012) 0.98
Analysis of microRNAs expressions in chondrosarcoma. J Orthop Res (2013) 0.98
MicroRNAs in Hepatobiliary and Pancreatic Cancers. Front Genet (2011) 0.98
miRNAs regulate expression and function of extracellular matrix molecules. Matrix Biol (2012) 0.98
Epigenetic regulation in human melanoma: past and future. Epigenetics (2015) 0.98
MicroRNA in cancer: new hopes for antineoplastic chemotherapy. Ups J Med Sci (2012) 0.98
AKT-ing via microRNA. Cell Cycle (2010) 0.97
MicroRNAs in lung cancer. World J Methodol (2014) 0.97
Non-coding RNAs as therapeutic targets in hepatocellular cancer. Curr Cancer Drug Targets (2012) 0.96
Therapeutics Based on microRNA: A New Approach for Liver Cancer. Curr Genomics (2010) 0.96
MicroRNAs and lung cancer: Biology and applications in diagnosis and prognosis. J Carcinog (2010) 0.96
CancerMA: a web-based tool for automatic meta-analysis of public cancer microarray data. Database (Oxford) (2012) 0.95
Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther (2014) 0.95
MiR-130b plays an oncogenic role by repressing PTEN expression in esophageal squamous cell carcinoma cells. BMC Cancer (2015) 0.93
The Stress-response protein prostate-associated gene 4, interacts with c-Jun and potentiates its transactivation. Biochim Biophys Acta (2013) 0.93
MicroRNA as tools and therapeutics in lung cancer. Respir Med (2015) 0.93
MicroRNA and its roles in esophageal cancer. Med Sci Monit (2012) 0.92
Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma. Pigment Cell Melanoma Res (2011) 0.92
MiR-221 and miR-130a regulate lung airway and vascular development. PLoS One (2013) 0.92
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
The functions of animal microRNAs. Nature (2004) 64.85
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res (2006) 39.25
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
A microRNA array reveals extensive regulation of microRNAs during brain development. RNA (2003) 9.76
Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res (2006) 8.26
The multiple roles of PTEN in tumor suppression. Cell (2000) 6.71
Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J (2007) 6.26
Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer (2005) 5.65
MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol (2008) 5.21
Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem (2003) 4.33
Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell (1989) 4.17
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene (2008) 4.11
MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer (2006) 4.11
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of FOS proteins. Oncogene (1991) 3.41
The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res (2008) 3.21
PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A (1998) 3.05
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology (2004) 2.91
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene (2008) 2.44
Molecular genetics of lung cancer. Annu Rev Med (2001) 2.25
Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest (1998) 2.02
Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene (1989) 1.92
Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res (1998) 1.83
Clarifications on miRNA and cancer. Science (2006) 1.69
The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J (1994) 1.68
Hepatocyte growth factor signaling pathway inhibits cholesterol 7alpha-hydroxylase and bile acid synthesis in human hepatocytes. Hepatology (2007) 1.47
The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci (2008) 1.28
Combined signaling through ERK, PI3K/AKT, and RAC1/p38 is required for met-triggered cortical neuron migration. J Biol Chem (2005) 1.26
Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer (2008) 1.25
PAK is regulated by PI3K, PIX, CDC42, and PP2Calpha and mediates focal adhesion turnover in the hyperosmotic stress-induced p38 pathway. J Biol Chem (2008) 1.24
Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res (2002) 1.21
Abnormal vessel formation in the choroid of mice lacking tissue inhibitor of metalloprotease-3. Invest Ophthalmol Vis Sci (2008) 1.15
The TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structure. Blood (2005) 1.08
Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res (2009) 1.07
Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res (2005) 1.05
Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo. Gene Ther (2003) 1.01
Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK. FEBS Lett (2008) 0.96
Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells. Cell Cycle (2007) 0.93
Akt regulates drug-induced cell death through Bcl-w downregulation. PLoS One (2008) 0.91
What goes up must come down. Nat Cell Biol (1999) 0.87
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A (2004) 13.66
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA (2007) 9.97
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol (2007) 8.05
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
MicroRNA-cancer connection: the beginning of a new tale. Cancer Res (2006) 7.38
A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24
Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res (2006) 5.72
Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol (2009) 5.56
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 5.07
Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res (2008) 4.64
MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol (2008) 4.10
MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A (2006) 3.80
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer (2007) 3.53
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem (2009) 3.16
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
ZEITLUPE is a circadian photoreceptor stabilized by GIGANTEA in blue light. Nature (2007) 3.00
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem (2008) 3.00
p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med (2011) 2.93
Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity (2010) 2.67
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell (2010) 2.59
microRNA-205 regulates HER3 in human breast cancer. Cancer Res (2009) 2.53
Concern Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A (2003) 2.52
Degos disease: a C5b-9/interferon-α-mediated endotheliopathy syndrome. Am J Clin Pathol (2011) 2.50
Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Lett (2009) 2.48
Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I. Science (2011) 2.47
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med (2011) 2.46
Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation (2012) 2.44
mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer (2007) 2.40
Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A (2007) 2.37
Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res (2010) 2.30
Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology (2009) 2.29
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2010) 2.28
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood (2010) 2.25
The SOC1 MADS-box gene integrates vernalization and gibberellin signals for flowering in Arabidopsis. Plant J (2003) 2.20
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation (2011) 2.18
Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood (2009) 2.18
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2009) 2.16
Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med (2013) 2.16
Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals. Am J Cardiol (2005) 2.14
Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res (2004) 2.08
Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A (2010) 2.05
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A (2010) 1.99
Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci U S A (2011) 1.96
Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res (2006) 1.96
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell (2006) 1.96
MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst (2010) 1.94
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A (2010) 1.94